| | Greg Yothers, PhD
Research Assistant Professor, Biostatistics
Statistician, NSABP EducationB.S., Pennsylvania State University
M.A., University of Pittsburgh
Ph.D., University of Pittsburgh Research Interests My research thus far is aimed at the general problem of identifying subsets of a population where treatments have a significant difference. I also am involved in applied statistics with the National Surgical Adjuvant Breast and Bowel Project (NSABP). I am responsible for managing the NSABP's colorectal clinical trials program and I have some responsibilities in the Quality of Life program ofresearch. Selected Publications
Patricia A. Ganz, Stephanie R. Land, Cynthia Antonio, Ping Zheng, Greg Yothers, Laura Petersen, D. Lawrence Wickerham, N. Wolmark, Clifford Y. Ko, Cancer Survivorship Research: The Challenge of Recruiting Adult Long Term Cancer Survivors from a Cooperative Clinical Trials Group, Journal of Cancer Survivorship, Published online ahead of print June 13, 2009, http://www.springerlink.com/content/268630u3n113r230/?p=645d33e4e925458a9f8413cc4ae787e5&pi=0
Carmen J. Allegra, Greg Yothers, Michael J. O’Connell, Saima Sharif, Linda H. Colangelo, Samia H. Lopa, Nicholas J. Petrelli, Richard M. Goldberg, James N. Atkins, Thomas E. Seay, Louis Fehrenbacher, Seamus O’Reilly, Louis Chu, Catherine A. Azar, and Norman Wolmark, Initial safety report of NSABP C-08: A randomized phase three study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer, Journal of Clinical Oncology, Published online ahead of print May 4, 2009, http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2009.21.9220
Daniel Sargent, Alberto Sobrero, Axel Grothey, Michael J. O'Connell, Marc Buyse, Thierry Andre, Yan Zheng, Erin Green, Roberto Labianca, Chris O'Callaghan, Jean Francois Seitz, Guido Francini, Daniel Haller, Greg Yothers, Richard Goldberg, and Aimery de Gramont, Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials, Journal of Clinical Oncology, Vol 27, No 6, February 20, 2009: 872-877, http://jco.ascopubs.org/cgi/content/abstract/27/6/872
Sharif, Saima, O'Connell, Michael J., Yothers, Greg, Lopa, Samia and Wolmark, Norman, FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer, Cancer Investigation, Vol. 26, No. 9, November 2008: 956-63, http://dx.doi.org/10.1080/07357900802132550
Green EM, Yothers G, Sargent Daniel J, Surrogate endpoint validation: statistical elegance versus clinical relevance, Statistical Methods in Medical Research, Vol. 17, No. 5, October 1, 2008: 477-86, http://smm.sagepub.com/cgi/content/abstract/17/5/477
Presentations
Greg Yothers, Neurotoxicity (NT) in colon cancer (CC) survivors from NSABP Protocol C-07 comparing 5-FU + leucovorin (FULV) with the same regimen + oxaliplatin (FLOX): Preliminary results from NSABP Protocol LTS-01, General Scientific Session, NSABP Group Meeting, Hollywood, FL, June 2008
Greg Yothers, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Survival following recurrence, Outcomes in White patients and those of African descent, and Time-dependent patterns of failure and treatment benefit: Findings from the 20,800 patient ACCENT dataset, General Scientific Session, NSABP Group Meeting, Jacksonville, FL, April 2007
Yothers G, NSABP C-08: A Clinical Trial Comparing Infusional 5-FU Oxaliplatin (mFOLFOX4) every two weeks with Bevacizumab to the same regimen without Bevacizumab for the treatment of patients w/resected Stages I and II carcinoma of the colon, American Society of Clinical Oncology, New Orleans LA, June 2004
Contact Information NSABP Biostatistical Center
201 North Craig Street, Suite 350
Pittsburgh, PA 15213
Telephone: 412-383-2558
Facsimile: 412-383-1387
Email: Yothers at nsabp.pitt.edu |  |
